SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

December 23, 2010 12:29 ET

Radient Pharmaceuticals Advised on Revised Date for Amex Application Review

TUSTIN, CA--(Marketwire - December 23, 2010) - Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today it has been advised by the American Stock Exchange ("AMEX"), that the Company's current application for the issuance of securities related to various Notes offerings that took place in 2008, 2009 and 2010 (these are the issuances that were approved by the Company's shareholders at the annual shareholder meeting on December 3, 2010) is scheduled to be reviewed by the AMEX listing committee on or about January 6, 2011. RPC anticipates, but cannot guarantee, that the listing committee will approve all of the share issuances noted in the application at such meeting. The Company will file a Current Report on Form 8-K to disclose and announce when Amex submits its approval. 

For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company's corporate website at or or For Investor Relations information contact Kristine Szarkowitz at or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring. The company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence. To learn more about our company, people and potentially life-saving cancer test, visit

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Contact Information

  • RPC Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    Email Contact
    (Tel : ) 206.310.5323